Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...

Swiss drug giant Novartis has cuts its 2007 turnover forecast after sales of its irritable bowel syndrome drug Zelnorm were suspended following fears raised by US regulators that the treatment could ...

The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...

High-profile, quick-growing IBS drug shelved because of cardio risks. FDA has asked Novartis to pull Zelnorm (tegaserod) from the market five years after its approval, eliciting a swift and surprised ...

WASHINGTON (Reuters) - Novartis will further restrict access to its irritable bowel syndrome drug Zelnorm, reserving it for the sickest patients, the company and U.S. health regulators said on ...

Goodbye cruel world. Novartis is pulling the irritable bowel med Zelnorm off the market almost completely, saying it will supply the drug only for emergency use. And even in emergencies, Zelnorm will ...

ZURICH, May 31 (Reuters) - Swiss health authorities ordered on Thursday the withdrawal of Novartis's Zelmac, known as Zelnorm in the United States, for the treatment of irritable bowel syndrome.

Having restricted its use last year, Novartis has now served notice that it intends to take its irritable bowel syndrome off the US market completely. Having restricted its use last year, Novartis has ...

Novartis AG’s decision to withdraw its Zelnorm irritable bowel treatment in the US last week because of side effects has left patients pondering their treatment options. Zelnorm was the only drug for ...